# A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.

> **NCT05286567** · PHASE1 · COMPLETED · sponsor: **Aarhus University Hospital** · enrollment: 15 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** RGRN-305
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05286567
- **Lead sponsor:** Aarhus University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-08-29
- **Final completion:** 2022-08-29
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05286567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05286567, "A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05286567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*